Ilmarinen Mutual Pension Insurance Co Has $8.12 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ilmarinen Mutual Pension Insurance Co increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,400 shares of the biopharmaceutical company’s stock after purchasing an additional 3,400 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Regeneron Pharmaceuticals were worth $8,121,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Integrated Wealth Concepts LLC boosted its position in shares of Regeneron Pharmaceuticals by 40.1% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock worth $786,000 after purchasing an additional 214 shares in the last quarter. IHT Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 17.2% in the third quarter. IHT Wealth Management LLC now owns 701 shares of the biopharmaceutical company’s stock worth $736,000 after acquiring an additional 103 shares in the last quarter. Stifel Financial Corp grew its stake in Regeneron Pharmaceuticals by 7.3% in the third quarter. Stifel Financial Corp now owns 48,245 shares of the biopharmaceutical company’s stock valued at $50,717,000 after acquiring an additional 3,271 shares during the period. Kovitz Investment Group Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 54.6% during the third quarter. Kovitz Investment Group Partners LLC now owns 3,691 shares of the biopharmaceutical company’s stock valued at $3,880,000 after acquiring an additional 1,303 shares in the last quarter. Finally, EP Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 16.6% during the third quarter. EP Wealth Advisors LLC now owns 1,467 shares of the biopharmaceutical company’s stock worth $1,542,000 after purchasing an additional 209 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $573.45 on Friday. The business’s 50 day simple moving average is $676.70 and its 200 day simple moving average is $779.13. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.00 and a 12 month high of $1,211.20. The company has a market cap of $62.69 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.86 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on REGN shares. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.